Skip to content
Home/Companies/Biotech/Tizona Therapeutics
Tizona Therapeutics

Tizona Therapeutics

Biotech·US·Active·10yr hold
Entry
2016
Hold
10yr
Status
Active

Who owns Tizona Therapeutics?

Tizona Therapeutics is currently owned by Abingworth through Abingworth Bioventures VI (2014 vintage), since 2016.

Hand-verified · updated 2026-06-10

Abingworth
Investor
Abingworth
Abingworth Bioventures VI · 2014 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Websitewww.tizonatx.com

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

Verona Pharma
Verona Pharma
Exited 2025
BiotechUK
to
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals
Active
HealthcareUS· 2022
Exicure
Active
BiotechUS· 2019
Soleno Therapeutics
Soleno Therapeutics
Exited 2026
BiotechUS· 2018
to
Median Technologies
Active
MedTechFrance· 2015
Avedro
Exited 2019
MedTechUS· 2014
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Tizona Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Tizona Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Tizona Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue